Table I.

General conditions of the patients.

Pt. no.	Age (years)	Gender	ECOG performance status	Pathological type	Stage	Extranodal organ involvement	Tumor (>10 cm)	Chemotherapy (x no. of cycles)	Other treatment	Response	Clinical course (months)
1	22	M	0	HL MC	IVB	Lung, spleen, marrow	0	ABVD x6 MOPP x3	Interferon	NR	18
2	26	M	1	HL NS	IVB	Lung, thoracic-abdominal wall, marrow	0	ABVD x4 MOPP x3	Radiotherapy	NR	16
3	36	M	1	NHL DLBCL	IVA	Liver, spleen, pancreas, marrow	0	CHOP x3 DICE x3	MabThera	NR	10
4	39	M	2	NHL ALXL	IVB	Liver, spleen, marrow	0	CHOP x3 CHOEP x3 DICE x2	Radiotherapy	NR	12
5	41	M	1	NHL SMZL	IVB	Liver, spleen, pancreas, thoracic wall, marrow	0	CHOP x5 ESHAP x3 DICE x3	MabThera	NR	35
6	45	M	0	NHL DLBCL	IVB	Lung, liver	0	CHOP x3 ESHAP x2 DICE x1	Interferon	NR	12
7	55	M	4	NHL ALXL	IVB	Lung, thoracic-abdominal wall, marrow	1	BCHOP x3 ESHAP x2 DICE x2	Radiotherapy	NR	13
8	65	M	3	NHL MCL	IVA	Lung, pancreas, liver, marrow	0	CHOP x3 DICE x3	MabThera	NR	12

M, male; HL, Hodgkin's lymphoma; NHL, non-Hodgkin's lymphoma; MC, mixed cellularity; NS, nodular sclerosis; DLBCL, diffuse large B-cell lymphoma; SMZL, splenic marginal zone lymphoma; MCL, mantle cell lymphoma; NR, no response.